- ￥2620 - 5240
- 爱必信(absin)
- abs172217
- 上海
- 2025年07月07日
- ELISA, Flow Cyt, Kinetics (BLI), Kinetics (SPR), Functional assay
- CHO
- -
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
Anti-Nectin-4 Reference Antibody(Enfortumab Vedotin-ejfv)
- 抗体英文名：
Anti-Nectin-4 Reference Antibody(Enfortumab Vedotin-ejfv)
- 靶点：
-
- 浓度：
-
- 应用范围：
ELISA, Flow Cyt, Kinetics (BLI), Kinetics (SPR), Functional assay
- 宿主：
CHO
- 适应物种：
-
- 保质期：
1年
- 抗原来源：
-
- 目录编号：
-
- 级别：
-
- 库存：
现货
- 供应商：
爱必信(上海)生物科技有限公司
- 标记物：
-
- 克隆性：
-
- 保存条件：
Store at -80℃ for one year.
- 形态：
液态
- 亚型：
-
- 免疫原：
-
- 规格：
100ug/1mg
| 规格： | 100ug | 产品价格： | ￥2620.0 |
|---|---|---|---|
| 规格： | 1mg | 产品价格： | ￥5240.0 |
| 概述 | |
| 描述 | 内毒素: <1 EU/mg; 纯度: >95% |
| 宿主 | CHO |
| 应用 | ELISA, Flow Cyt, Kinetics (BLI), Kinetics (SPR), Functional assay |
| 分子量 | 145.44 kDa |
| 性能 | |
| 纯化方法 | Protein A affinity column |
| 类型 | Monoclonal Antibody |
| 同种型 | IgG |
| 储存/保存方法 | Store at -80℃ for one year. |
| 存储溶液 | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 312 |
| 靶标 | |
| 背景说明 | Enfortumab vedotin-ejfv is an ADC consisting of a Nectin-4-directed antibody and Monomethyl auristatin E (MMAE) , suitable for adult patients with locally advanced or metastatic urothelial carcinoma, or who have received programmed cell death protein 1 (PD-1) inhibitor or programmed cell death ligand 1 (PD-L1) inhibitor therapy or neoadjuvant/adjuvant platinum-based chemotherapy for locally advanced or metastatic cancer. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验a simple ELISA method to detect human anti-antibody response.
Purification Of Anti Peptide Antibody
antibody that could contribute to staining background. The proportion in each pool varies with the peptide immunogen. The quality of the anti-peptide serum seems to increase with multiple boosts - the first bleed may be feeble.
Anticardiolipin Antibody and Anti-beta 2 Glycoprotein I Antibody Assays
standard” laboratory test to diagnose or classify a patient as having APS. This chapter discusses the clinical and laboratory theoretical and technical aspects of aCL and anti-β2GPI antibody assays.
